Lisanti Capital Growth LLC increased its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report) by 48.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 129,250 shares of the company’s stock after acquiring an additional 41,945 shares during the quarter. Kiniksa Pharmaceuticals International comprises 2.6% of Lisanti Capital Growth LLC’s investment portfolio, making the stock its 3rd largest holding. Lisanti Capital Growth LLC owned approximately 0.17% of Kiniksa Pharmaceuticals International worth $9,643,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Jacobi Capital Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the third quarter worth about $48,000. Ethic Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at approximately $726,000. Pictet Asset Management Holding SA boosted its holdings in Kiniksa Pharmaceuticals International by 41.3% in the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after buying an additional 251,578 shares during the period. AlphaCentric Advisors LLC bought a new position in Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $596,000. Finally, Commonwealth Equity Services LLC boosted its holdings in Kiniksa Pharmaceuticals International by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock worth $811,000 after buying an additional 237 shares during the period. 53.95% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
KNSA has been the topic of a number of analyst reports. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Wedbush raised their target price on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. Canaccord Genuity Group lifted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Finally, The Goldman Sachs Group upped their price target on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.
Check Out Our Latest Report on KNSA
Insider Activity
In other Kiniksa Pharmaceuticals International news, CFO Mark Ragosa sold 36,783 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $92.16, for a total transaction of $3,389,921.28. Following the sale, the chief financial officer directly owned 20,854 shares of the company’s stock, valued at approximately $1,921,904.64. The trade was a 63.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John Paolini sold 18,413 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $93.39, for a total value of $1,719,590.07. Following the completion of the transaction, the insider directly owned 69,922 shares of the company’s stock, valued at $6,530,015.58. This represents a 20.84% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 831,022 shares of company stock worth $77,475,599. 51.98% of the stock is owned by company insiders.
Kiniksa Pharmaceuticals International Stock Performance
KNSA stock opened at $95.76 on Thursday. Kiniksa Pharmaceuticals International, plc has a 52 week low of $37.02 and a 52 week high of $99.31. The firm’s fifty day moving average is $81.53 and its 200 day moving average is $62.18. The firm has a market cap of $7.52 billion, a P/E ratio of 73.66 and a beta of 0.07.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. The firm had revenue of $285.97 million during the quarter, compared to the consensus estimate of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. As a group, analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current year.
Kiniksa Pharmaceuticals International Company Profile
Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.
Featured Articles
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report).
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
